<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="254">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04317092</url>
  </required_header>
  <id_info>
    <org_study_id>TOCIVID-19</org_study_id>
    <secondary_id>2020-001110-38</secondary_id>
    <nct_id>NCT04317092</nct_id>
  </id_info>
  <brief_title>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</brief_title>
  <acronym>TOCIVID-19</acronym>
  <official_title>Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study project includes a single-arm phase 2 study and a parallel observational cohort
      study, enrolling patients with COVID-19 pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2 study: this is a multicenter, single-arm, open-label, phase 2 study. All the patients
      enrolled are treated with tocilizumab. One-month mortality rate is the primary endpoint.

      Observational cohort: patients who are treated with tocilizumab and cannot enter the phase 2
      study because:

        1. emergency conditions or infrastructural or operational limits prevented registration
           before the administration of the experimental drug or

        2. they had been intubated more than 24 hours before registration or

        3. the phase 2 study has been closed due to reached sample size.

      This means that, after closure of the phase 2 enrolment, patients who might be eligible for
      the phase 2 study will be included in the observational cohort study.

      The same information planned for the phase 2 cohort is in principle required also for the
      observational cohort study. The sample size of the observational study is not defined a
      priori, and the cohort will close at the end of the overall project. All the patients
      enrolled are treated with tocilizumab.

      In both study groups (phase 2 and observational study), participants will receive two doses
      of Tocilizumab 8 mg/kg (up to a maximum of 800mg per dose), with an interval of 12 hours.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2020</start_date>
  <completion_date type="Anticipated">December 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 19, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a multicenter, single-arm, open-label, phase 2 study. All the patients enrolled are treated with tocilizumab</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>One-month mortality rate</measure>
    <time_frame>up to 1 month</time_frame>
    <description>1-month mortality is defined as the ratio of patients who will alive after 1month from study start out of those registered at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6 level</measure>
    <time_frame>baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 month</time_frame>
    <description>IL-6 levels will be assessed using commercial ELISA method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte count</measure>
    <time_frame>baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 month</time_frame>
    <description>Lymphocyte count assessed by routinely used determination of blood count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP (C-reactive protein) level</measure>
    <time_frame>baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 month</time_frame>
    <description>CRP is assessed by routinely used determination of CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)</measure>
    <time_frame>baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 month</time_frame>
    <description>calculated from arterial blood gas analyses (values from 300 to 100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the SOFA (Sequential Organ Failure Assessment)</measure>
    <time_frame>baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 month</time_frame>
    <description>It evaluates 6 variables, each representing an organ system (one for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems), and scored from 0 (normal) to 4 (high degree of dysfunction/failure). Thus, the maximum score may range from 0 to 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0</measure>
    <time_frame>during treatment and up to 30 days after the last treatment dose</time_frame>
    <description>graded according to CTCAE citeria (v5.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological response</measure>
    <time_frame>at baseline (optional), after seven days and if clinically indicated (up to 1 month)</time_frame>
    <description>Thoracic CT scan or Chest XR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>from baseline up to patient's discharge (up to 1 month)</time_frame>
    <description>Days of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission of respiratory symptoms</measure>
    <time_frame>up to 1 month</time_frame>
    <description>time to invasive mechanical ventilation (if not previously initiated) calculated from baseline to intubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission of respiratory symptoms</measure>
    <time_frame>up to 1 month</time_frame>
    <description>time to definitive extubation calculated from intubation (any time occurred) to extubation in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission of respiratory symptoms</measure>
    <time_frame>up to 1 month</time_frame>
    <description>time to independence from non-invasive mechanical ventilation calculated in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission of respiratory symptoms</measure>
    <time_frame>up to 1 month</time_frame>
    <description>time to independence from oxygen therapy in days</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>tocilizumab treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All the patients enrolled are treated with tocilizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab Injection</intervention_name>
    <description>Tocilizumab 8 mg/kg (up to a maximum of 800mg per dose), with an interval of 12 hours.</description>
    <arm_group_label>tocilizumab treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Any gender

          2. No age limit

          3. Informed consent for participation in the study (consent can be oral if a written
             consent cannot be expressed. If the subject is incapable of giving an informed consent
             and an authorized representative is not available without a delay that would, in the
             opinion of the Investigator, compromise the potential life-saving effect of the
             treatment this can be administered without consent. Consent to remain in the research
             should be sought as soon the conditions of the patient will allow it)

          4. Virological diagnosis of SARS-CoV-2 infection (real-time PCR)

          5. Hospitalized due to clinical/instrumental diagnosis of pneumonia

          6. Oxygen saturation at rest in ambient air ≤93% or requiring oxygen therapy or
             mechanical ventilation either non invasive or invasive (intubated)

          7. Patients with criteria #4 and #5 who have been already treated with tocilizumab before
             registration are eligible for the observational retrospective cohort

        Exclusion Criteria:

          1. Known hypersensitivity to tocilizumab or its excipients

          2. Known active infections or other clinical condition that contraindicate tocilizumab
             and cannot be treated or solved according to the judgement of the clinician

          3. ALT / AST&gt; 5 times the upper limit of the normality

          4. Neutrophils &lt;500 / mmc

          5. Platelets &lt;50.000 / mmc

          6. Bowel diverticulitis or perforation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Perrone, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Perrone, MD, PhD</last_name>
    <phone>+390815903571</phone>
    <email>f.perrone@istitutotumori.na.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Carmela Piccirillo, MD</last_name>
    <phone>+390815903615</phone>
    <email>m.piccirillo@istitutotumori.na.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;SS. Antonio e Biagio e C. Arrigo&quot; (Dipartimento Internistico SSD Reumatologia)</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stobbione Paolo, MD</last_name>
      <phone>0131/206860</phone>
      <email>pstobbione@ospedale.al.it</email>
    </contact>
    <investigator>
      <last_name>Stobbione Paolo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive)</name>
      <address>
        <city>Busto Arsizio</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Franzetti, MD</last_name>
      <phone>0331/699270</phone>
      <email>fabio.franzetti@asst-valleolona.it</email>
    </contact>
    <investigator>
      <last_name>Fabio Franzetti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza)</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arturo Montineri, MD</last_name>
    </contact>
    <investigator>
      <last_name>Arturo Montineri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salvo Nicosia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppe Carpinteri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O.</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmelo Iacobello, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carmelo Iacobello, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Concetta Monea, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive)</name>
      <address>
        <city>Cosenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Mastroianni, MD</last_name>
      <phone>0984-681833</phone>
      <email>antoniomastroianni@yahoo.it</email>
    </contact>
    <contact_backup>
      <last_name>Antonio Mastroianni, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>ASST OVEST MILANESE presidi Legnano - Magenta</name>
      <address>
        <city>Magenta</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Faggioli, MD</last_name>
      <phone>0331449175-919</phone>
      <email>paola.faggioli@sst-ovestmi.it</email>
    </contact>
    <investigator>
      <last_name>Paola Faggioli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Modena</name>
      <address>
        <city>Modena</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Salvarani, MD</last_name>
      <phone>+39 0522 296684</phone>
      <email>salvarani.carlo@ausl.re.it</email>
    </contact>
    <investigator>
      <last_name>Carlo Salvarani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I)</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Girardis, MD</last_name>
      <phone>0594225868</phone>
      <email>ricercainnovazione@aou.mo.it</email>
    </contact>
    <investigator>
      <last_name>Massimo Girardis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II)</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabetta Bertelli, MD</last_name>
      <phone>0594225868</phone>
      <email>ricercainnovazione@aou.mo.it</email>
    </contact>
    <investigator>
      <last_name>Elisabetta Bertelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive)</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Mussini, MD</last_name>
      <phone>0594223673</phone>
      <email>nb.protocolli@unimore.it</email>
    </contact>
    <investigator>
      <last_name>Cristina Mussini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Clini, MD</last_name>
      <phone>0594225868</phone>
      <email>ricercainnovazione@aou.mo.it</email>
    </contact>
    <investigator>
      <last_name>Enrico Clini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia)</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Montesarchio, MD</last_name>
      <phone>+39 0817065268</phone>
      <email>vincenzo.montesarchio@ospedaledeicolli.it</email>
    </contact>
    <investigator>
      <last_name>Vincenzo Montesarchio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Ascierto, MD</last_name>
      <phone>+39 0815903431</phone>
      <email>p.ascierto@istitutotumori.na.it</email>
    </contact>
    <investigator>
      <last_name>Paolo Ascierto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva)</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiorentino Fragranza, MD</last_name>
      <phone>+39 08170672571</phone>
      <email>fiorentino.fragranza@ospedaledeicolli.it</email>
    </contact>
    <investigator>
      <last_name>Fiorentino Fragranza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio)</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Parrella, MD</last_name>
      <phone>+39 0817067584</phone>
      <email>roberto.parrella@ospedaledeicolli.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Parrella, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza)</name>
      <address>
        <city>Pesaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giancarlo Titolo, MD</last_name>
      <phone>328 4157022</phone>
      <email>giancarlo.titolo@ospedalimarchenord.it</email>
    </contact>
    <investigator>
      <last_name>Giancarlo Titolo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli</name>
      <address>
        <city>Pozzuoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Giuliano Numis, MD</last_name>
      <email>fabiogiuliano.numis@aslnapoli2nord.it</email>
    </contact>
    <investigator>
      <last_name>Fabio Giuliano Numis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione)</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Fusari, MD</last_name>
      <phone>0544285918</phone>
      <email>maurizio.fusari@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Maurizio Fusari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grande Ospedale Metropolitano, Reggio Calabria</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Demetrio Labate, MD</last_name>
      <phone>340 0940460</phone>
      <email>labatedemtrio84@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Demetrio Labate</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive)</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Cristini, MD</last_name>
      <phone>0541705506 - 0541705315</phone>
      <email>francesco.cristini@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Cristini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche)</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Cauda, MD</last_name>
      <phone>06 3015 4945</phone>
      <email>roberto.cauda@policlinicogemelli.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Cauda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Sette Laghi (Dipartimento di Medicina Interna)</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Dentali, MD</last_name>
      <phone>0332/393056</phone>
      <email>francesco.dentali@asst-settelaghi.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Dentali, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Sette Laghi (Dipartimento Emergenze ed Urgenze)</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Ageno, MD</last_name>
      <phone>0332/393056</phone>
      <email>walter.ageno@asst-settelaghi.it</email>
    </contact>
    <investigator>
      <last_name>Walter Ageno, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale)</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Cabrini, MD</last_name>
      <phone>0332/393056</phone>
      <email>l.cabrini@asst-settelaghi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali)</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Grossi, MD</last_name>
      <phone>0332/393056</phone>
      <email>paolo.grossi@asst-settelaghi.it</email>
    </contact>
    <investigator>
      <last_name>Paolo Grossi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Integrata di Verona (Dip. Malattie Infettive)</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelina Tacconelli, MD</last_name>
      <phone>045 8128243 - 8128244</phone>
      <email>evelina.tacconelli@univr.it</email>
    </contact>
    <investigator>
      <last_name>Evelina Tacconelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Magalini (U.O. Malattie Infettive)</name>
      <address>
        <city>Villafranca Di Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Danzi, MD</last_name>
      <phone>331/6237628</phone>
      <email>maria.danzi@aulss9.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Maria Danzi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://usc-intnapoli.net</url>
    <description>sponsor web-site for study conduction</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2020</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>pneumonia</keyword>
  <keyword>tocilizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared upon reasonable request to the Principal Investigator of the study
The following IPD will be available for sharing:
Baseline characteristics of patients
Treatment data
Safety data
Follow-up data</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>After peer-reviewed publication of the primary results, with no time limits</ipd_time_frame>
    <ipd_access_criteria>Motivated requests to access to IPD are to be sent by email to the Principal Investigator (f.perrone@istitutotumori.na.it)</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

